drugset / Trial / NCT02722265

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

NCT02722265

Phase 3 Completed 368 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

To examine antihypertensive effect, pharmacodynamics, and safety of long-term administration of CS-3150 as monotherapy and in combination with calcium channel blocker or renin-angiotensin system inhibitor in patients with essential hypertension.

Timeline

Start
2016-03
Primary completion
2017-07-08
Completion
2017-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CS-3150 Unknown 2.5 mg Oral
Subject CS-3150 Unknown 5 mg Oral